Ovitex was TELA Bio’s largest revenue line in fiscal 2025, bringing in $51.22M of $80.28M (64%).
| Customer | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Ovitex | $28.88M | $39.42M | $45.93M | $51.22M | |||
| Ovitex Prs | $12.43M | $18.74M | $22.75M | $27.31M | |||
| Other | $108.00K | $301.00K | $630.00K | $1.75M | |||
| Total | $41.42M | $58.45M | $69.30M | $80.28M |
TELA Bio brought in $80.28M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 15.8% from $69.30M in fiscal 2024. Ovitex was the largest at $51.22M (63.8%), ahead of Ovitex Prs at $27.31M (34.0%) and Other at $1.75M (2.2%).
Compared with fiscal 2024, Other grew fastest, up 177.0% to $1.75M. Every revenue line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $41.42M to $80.28M, a compound annual growth rate of 24.7%. Ovitex's share of the total fell from 69.7% to 63.8%.
TELA Bio (TELA) reports its revenue by customer. In fiscal 2025, Ovitex was its largest revenue line, bringing in $51.22M (63.8% of the total), followed by Ovitex Prs at $27.31M (34.0%).
Ovitex was TELA Bio's largest revenue line in fiscal 2025, bringing in $51.22M, or 63.8% of the $80.28M total across its three revenue lines.
Among TELA Bio's revenue lines that make up at least 2% of revenue, Other grew fastest in fiscal 2025, up 177.0% from $630.00K to $1.75M.
Every figure comes from TELA Bio's annual financial filings, as reported. Each line keeps the name TELA Bio gives it, and years follow its fiscal calendar.
TELA Bio's revenue by customer goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.